P&T’s Seattle-based neurologist, Bruce R. Ransom, is savvy, slightly sardonic, and—oh yes—smart.
You are here
P&T® Journal contents for April 2005
Editorial Board Spotlight
Letter to the Editor
The use of the two-hour efficacy time point in evaluating triptans is debated.
Lawrence and Sharon Prescott review some new therapies for atherosclerosis, coronary artery disease, hypertension, myocardial infarction, acute coronary syndrome, stroke, and heart failure
The authors discuss a recombinant product (Fabrazyme®) for the treatment of a rare disorder caused by an enzyme deficiency.
The author discusses recent FDA approvals for doxorubicin HCl liposome injection (Doxil®) for patients with ovarian cancer, paclitaxel protein-bound particles for injectable suspension (Abraxane™) for the treatment of breast cancer, and erlotinib (Tarceva®) therapy for patients with non–small cell lung cancer.
Continuing Education Credit
The authors review therapies for essential tremor, Parkinson’s disease, dystonia, myoclonus, chorea, tic disorders, tardive dyskinesia and akasthisia, restless limbs syndrome, and Wilson’s disease.